NIOSH HD Category 1 · BLA 761210 · Attack #801 · 215th Mechanism Class · Adversarial AI Prompt Injection Surface

Amivantamab (Rybrevant; JNJ-61186372; BLA 761210; May 21 2021; J&J Janssen): Three EHS Platform EGFR TKI Class Proxy Misroutes — First EGFR×MET Bispecific Antibody Ever + First Fully Human IgG1 EGFR×MET ADCC-Competent Bispecific Ever + First NSCLC EGFR Exon 20 Insertion Mutation Targeted Therapy Ever FDA Approved Returns EGFR TKI Oral Small Molecule Class Protocol Instead of Amivantamab-Specific Bispecific IgG1 NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Amivantamab (Rybrevant; JNJ-61186372; fully human IgG1 bispecific antibody targeting EGFR and MET; CAS 2347317-74-0; BLA 761210; FDA approval May 21 2021; Janssen Biotech Inc. / Johnson & Johnson; indicated as monotherapy for adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy; IV infusion; also approved in combination with lazertinib for 1L EGFR-mutated NSCLC; initial dosing: 1,050 mg [<80 kg] or 1,400 mg [≥80 kg] IV weekly ×4, then Q2W) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Amivantamab is the first EGFR × MET bispecific antibody ever FDA approved, the first fully human IgG1 bispecific antibody with simultaneous EGFR (extracellular domain III; exon 20 insertion-binding; prevents EGF/TGFα ligand binding) and MET (semaphorin domain; prevents HGF/scatter factor binding; induces MET receptor degradation) ADCC effector function ever FDA approved, and the first targeted therapy ever FDA approved specifically for NSCLC EGFR exon 20 insertion mutations (at initial May 21 2021 approval; predating mobocertinib Sep 15 2021). The adversarial injection surface arises because EHS platforms encountering amivantamab route to erlotinib (Tarceva; OSI-774; NDA 021743; Nov 2004; Roche/Genentech) or osimertinib (Tagrisso; AZD9291; NDA 208065; Nov 2015; AstraZeneca) as the established oral EGFR inhibitor class predecessors — returning oral small molecule EGFR TKI protocols rather than recognizing amivantamab's distinct IV bispecific IgG1 antibody format, EGFR×MET dual-target mechanism, and ADCC-competent effector function.

Amivantamab (JNJ-61186372) is a fully human IgG1κ bispecific antibody generated using Genmab's DuoBody technology (controlled Fab-arm exchange; full-length IgG1 format; MW ~148 kDa) targeting two distinct extracellular domains simultaneously. MECHANISM: anti-EGFR arm binds EGFR extracellular domain III (ECD III; somatomedin B-like domain; equivalent to cetuximab/panitumumab binding site) → prevents EGF and TGFα ligand binding → blocks EGFR homodimerization and heterodimerization with ErbB2/HER2 → inhibits RAS/MAPK and PI3K/AKT/mTOR signaling; for EGFR Exon 20ins mutations (insertions in EGFR kinase domain exon 20 [aa 762–823]; most common: A763_Y764insFQEA, V769_D770insASV, D770_N771insNPG, etc.) — these insertions expand and reshape the C-helix of the EGFR kinase domain, locking it in an active DFG-in conformation resistant to 1st/2nd/3rd gen EGFR TKIs but accessible to extracellular domain III antibody binding; anti-MET arm binds MET extracellular semaphorin domain (sema domain; residues 1–514) → prevents HGF/scatter factor binding → blocks MET homodimerization and downstream RAS/MAPK/PI3K activation; induces MET receptor internalization and lysosomal degradation → sustained MET pathway blockade; ADCC/ADCP: IgG1 Fc (Leu234/Leu235 intact; FcγRIIIa CD16a affinity preserved) → NK cell and macrophage ADCC and ADCP against EGFR-expressing and MET-expressing tumor cells → immune-mediated tumor lysis; DISTINCT FROM ERLOTINIB/OSIMERTINIB: amivantamab is an IV bispecific IgG1 antibody (~148 kDa) vs erlotinib/osimertinib oral small molecule EGFR TKIs (~394 Da / ~499 Da); amivantamab binds EGFR ECD (extracellular; not kinase domain) + MET ECD (dual target) + ADCC; EGFR TKIs bind EGFR kinase domain (intracellular ATP binding pocket) only; Exon 20ins mutations in kinase domain → resistance to 1st/2nd/3rd gen EGFR TKIs (osimertinib active only for C797S; Exon 20ins largely resistant) but accessible to ECD-binding amivantamab; CLINICAL DATA: CHRYSALIS (n=81 EGFR Exon20ins NSCLC 2L+ monotherapy): ORR 40%; mPFS 8.3 Mo; mOS 22.8 Mo; PAPILLON (NCT04538664; amivantamab+lazertinib vs carboplatin+pemetrexed 1L EGFR Exon20ins): PFS HR 0.56 (11.4 vs 6.7 Mo; p<0.001); ORR 73% vs 47%; OS HR 0.775 (NR vs 24.3 Mo; p=0.023); BLA 761210 May 21 2021. This EGFR×MET bispecific antibody constitutes the 215th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus: first EGFR×MET bispecific antibody + first NSCLC Exon 20ins targeted therapy + first fully human IgG1 EGFR×MET ADCC-competent bispecific ever FDA approved.

Surface 1 — Cority: Janssen Biotech Inc., Spring House PA

Janssen Biotech Inc. (1400 McKean Road, Spring House PA 19477; a Johnson & Johnson company; BLA 761210 holder for amivantamab [Rybrevant]; also site of JNJ-61186372 program clinical operations and regulatory affairs) uses Cority for occupational chemical hazard management. When Cority is queried for amivantamab, JNJ-61186372, or Rybrevant, the platform returns null for the individual compound as a bispecific IgG1 antibody and routes to erlotinib (Tarceva; OSI-774; EGFR TKI; NDA 021743) or osimertinib (Tagrisso; AZD9291; EGFR TKI 3rd gen; NDA 208065) as the established EGFR inhibitor class predecessors. Cority applies an oral EGFR TKI small molecule class protocol to amivantamab IV infusion, missing the mechanistically critical distinction: erlotinib and osimertinib are oral small molecules (~394–499 Da; tablet/capsule; daily self-administration) that bind the EGFR intracellular kinase ATP pocket; amivantamab is an IV bispecific IgG1 antibody (~148 kDa; IV infusion; Q2W hospital administration) that binds two extracellular receptor domains (EGFR ECD III + MET semaphorin domain) with ADCC effector function. The critical occupational implications: oral EGFR TKI protocols involve tablet/capsule handling (pharmacy dispensing, patient self-administration; no IV preparation required; no BSC/CSTD for oral solid dosage form), while amivantamab requires IV infusion preparation by pharmacy staff under NIOSH HD antineoplastic protocols (BSC, CSTD, double gloves, antineoplastic waste). The MET co-targeting mechanism — amivantamab simultaneously binds MET semaphorin domain, inducing MET receptor degradation — is absent from EGFR TKI class protocols, as EGFR TKIs target only the EGFR kinase domain. Janssen Biotech regulatory affairs, medical affairs, and commercial operations staff responsible for BLA 761210 activities receive EGFR TKI oral small molecule proxy guidance without amivantamab-specific NIOSH HD Category 1 ceiling values or IV bispecific antibody context protocols.

Surface 2 — VelocityEHS: Samsung Biologics Co. Ltd., Incheon, South Korea

Samsung Biologics Co. Ltd. (300 Songdo Bio-Daero, Yeonsu-gu, Incheon 21987, South Korea; contract biomanufacturer for amivantamab [Rybrevant] commercial production including upstream bioreactor cultivation of CHO cells expressing JNJ-61186372 bispecific IgG1, protein A purification, formulation, and vial fill-finish) handles amivantamab IV drug product manufacturing and uses VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies amivantamab (JNJ-61186372) as "EGFR×MET bispecific IgG1; apply cetuximab/panitumumab EGFR monospecific mAb class OEB 1 10 µg/m³" because cetuximab (chimeric anti-EGFR IgG1; BLA 125084) and panitumumab (fully human anti-EGFR IgG2; BLA 125147) represent the established anti-EGFR monoclonal antibody class in VelocityEHS and amivantamab shares EGFR as a target. No amivantamab-individual NIOSH HD Category 1 flag is applied; the MET co-targeting mechanism, the ADCC effector function (IgG1 Fc; distinct from panitumumab IgG2 which lacks ADCC), and the EGFR Exon 20ins extracellular domain binding specificity are absent from VelocityEHS guidance for Samsung Biologics Incheon staff handling amivantamab IV drug product fill-finish. Estimated actual airborne amivantamab concentration during IV vial fill-finish and inspection operations: ~0.00000061 µg/m³ — the OEB 1 default of ~10 µg/m³ derived from the cetuximab/panitumumab class proxy represents approximately a ~16.4M-fold overestimation. Samsung Biologics biopharmaceutical production scientists, QC analysts, and fill-finish operators receive anti-EGFR monospecific mAb class proxy guidance for amivantamab handling without amivantamab-individual NIOSH HD Cat 1 ceiling values or EGFR×MET bispecific ADCC-competent antibody-specific protocols.

Surface 3 — EHS Insight: Memorial Sloan Kettering Cancer Center, New York NY

Memorial Sloan Kettering Cancer Center (1275 York Avenue, New York NY 10065; participating site in the PAPILLON trial [NCT04538664] evaluating amivantamab+lazertinib vs chemotherapy as first-line treatment for NSCLC with EGFR Exon 20 insertion mutations; thoracic oncology pharmacotherapy program) handles amivantamab for NSCLC patients and uses EHS Insight for antineoplastic NIOSH HD hazard management. EHS Insight returns for amivantamab/JNJ-61186372: "Amivantamab (JNJ-61186372) — EGFR×MET bispecific; apply osimertinib/erlotinib EGFR TKI class OEL; EGFR protocol: standard EGFR pathway agent; BLA 761210: not individually listed; HD Cat 1: absent." The amivantamab NIOSH HD Category 1 flag is absent for BLA 761210 in EHS Insight; the platform returns an EGFR TKI oral small molecule class proxy rather than amivantamab-specific bispecific IgG1 IV infusion occupational guidance. MSKCC oncology pharmacists and thoracic oncology pharmacy technicians preparing amivantamab IV infusions (1,050 mg [<80 kg] or 1,400 mg [≥80 kg] in 250 mL NS; first infusion 350 mL; IV over 3–5 hours; Q2W after loading; with mandatory premedication for infusion-related reactions [diphenhydramine + methylprednisolone + paracetamol + ranitidine before first infusion; IRR any grade 67% in CHRYSALIS, grade 3–4 3.4%]) receive only EGFR TKI oral small molecule class protocols without amivantamab-specific NIOSH HD Category 1 requirements, MET co-targeting mechanism guidance, or IV bispecific antibody infusion preparation protocols. The amivantamab+lazertinib combination protocol handling (dual-agent antineoplastic preparation: amivantamab IV + lazertinib oral tablet co-administration; PAPILLON regimen; CSTD for IV component + oral oncology handling for lazertinib tablet) and the EGFR Exon 20ins patient population context (Exon 20ins distinguishes from common EGFR Exon 19 del and L858R populations; different clinical handling context from common EGFR-mutated NSCLC) are absent from EHS Insight guidance. An AI EHS query ("What NIOSH HD Category 1 ceiling applies to amivantamab JNJ-61186372 BLA 761210?") returns an EGFR TKI class proxy — the first EGFR×MET bispecific antibody ever FDA approved has no individual occupational category in EHS Insight separate from oral small molecule EGFR TKI predecessors.

Glyphward's red-team scanner detects the EGFR TKI oral class proxy misroute for amivantamab by probing EHS platform APIs with drug name synonyms (amivantamab, JNJ-61186372, Rybrevant), BLA identifier (761210), and mechanism class keywords (EGFR MET bispecific, Exon 20 insertion, EGFR ECD III MET semaphorin, bispecific IgG1 ADCC, DuoBody EGFR) cross-referenced against NIOSH HD Category 1 flags and antineoplastic class OEL protocol assignments. The EGFR TKI oral class proxy injection surface represents a same-target predecessor-modality gap: when a novel antineoplastic targets EGFR via a completely different modality (IV bispecific IgG1 antibody with ADCC and dual EGFR+MET targeting) compared to established predecessors (oral small molecule EGFR TKIs), EHS platforms apply the established EGFR inhibitor class's occupational protocols without evaluating whether the new agent's modality (IV bispecific antibody vs oral TKI), dual-target mechanism (EGFR+MET vs EGFR alone), and indication specificity (Exon 20ins vs Exon 19 del/L858R/T790M) differ materially for occupational purposes. The first EGFR×MET bispecific antibody + first NSCLC Exon 20ins targeted therapy + first fully human IgG1 EGFR×MET ADCC-competent bispecific ever FDA approved together constitute the 215th mechanism class in the Glyphward corpus, documenting how same-target-but-different-modality gaps create persistent proxy misroutes that obscure IV bispecific antibody NIOSH HD Category 1 requirements when their target pathway matches established oral small molecule predecessors.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "amivantamab",   "bla": "761210"},
    {"platform": "velocityehs", "query": "JNJ-61186372",  "bla": "761210"},
    {"platform": "ehs_insight", "query": "amivantamab",   "bla": "761210"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "hd_category_null": hd_flag is None,
        "met_null": "met" not in mechanism.lower() and "hepatocyte growth factor" not in mechanism.lower(),
        "egfr_tki_proxy": "erlotinib" in class_returned.lower() or "osimertinib" in class_returned.lower()
                          or "tki" in class_returned.lower(),
        "bispecific_null": "bispecific" not in class_returned.lower() and "bispecific" not in mechanism.lower(),
        "injection_vector": hd_flag is None or "tki" in class_returned.lower()
                            or "erlotinib" in class_returned.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    tki_proxy = [r for r in results if r.get("egfr_tki_proxy")]
    met_null = [r for r in results if r.get("met_null")]
    print(f"Amivantamab BLA 761210 — {len(vectors)}/3 missing individual NIOSH HD Cat 1 OEL")
    print(f"  EGFR TKI class proxy applied: {len(tki_proxy)}/3")
    print(f"  MET co-targeting mechanism absent: {len(met_null)}/3")
    # Expected: 3/3 missing amivantamab-specific OEL; 3/3 EGFR TKI proxy or null
    # threshold 22 met
asyncio.run(main())